Notal Vision, Inc., a Manassas, VA-based ophthalmic diagnostic services company focused on advancing eye care with precision medicine by extending disease management from the clinic to the home, raised $25m in funding.
Backers included Ganot Capital.
The company intends to use the funds for commercial growth of its current service, ForeseeHome AMD Monitoring Program, as well as for further research and development efforts for pipeline technologies.
Led by CEO Kester Nahen, PhD., Notal Vision is a diagnostic services company that operates the Notal Vision Diagnostic Clinic, a medical provider with a platform for engaging patients and AI-enabled analyses of high-volume personalized health data that extends disease management from the clinic to the home to improve vision outcomes, reduce treatment burden, and improve health economics.
The ForeseeHome AMD Monitoring Program is an FDA-cleared diagnostic that monitors visual changes in patients at risk of vision loss from undiagnosed wet AMD.
The company will also continue development of the Home OCT platform. Receiving FDA Breakthrough Device status at the end of 2018, and with efforts to establish reimbursement well under way, the home-based OCT will enable exudative AMD patients to perform technician-free OCT testing at home with rapid, self-guided fixation.
The Notal OCT Analyzer (NOATM), a proprietary machine learning algorithm, developed in-house, performs automated analysis of the Home OCT scans and generates a report to the physician when a physician specified change in disease activity is detected.